An Open-label Study of Leukocyte Counts in the Cerebrospinal Fluid and Blood of Subjects With Relapsing Forms of Multiple Sclerosis Following Treatment With Firategrast.
Phase of Trial: Phase II
Latest Information Update: 27 Mar 2017
At a glance
- Drugs Firategrast (Primary)
- Indications Multiple sclerosis
- Focus Pharmacodynamics
- Sponsors GlaxoSmithKline
- 10 Jun 2017 Biomarkers information updated
- 16 Mar 2010 Actual patient number (46) added as reported by ClinicalTrials.gov.
- 16 Mar 2010 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.